Data source: A randomized, placebo-controlled, dose-ranging trial enrolling 299 adult patients with anogenital warts
from 40 European clinics between 2001 and 2003.
Anaconda concluded a Phase IIa clinical trial in 2013, that it said showed AP611074 was secure and effective in eliminating or reducing anogenital warts
when used as a topical gel over six weeks of treatment.
In addition, a reduction in cases of anogenital warts
among both females and males younger than 21 years was seen within two years of the vaccine's introduction (Read et al, 2011) even though the HPV vaccine was not introduced for males until 2013, showing a herd immunity effect.
Prevalence, incidence and risk factors for anogenital warts
in Sub Saharan Africa: A systematic review and meta analysis.
Nonsexual transmission of anogenital warts
in children:a retrospective analysis.
Enrollment in the ongoing Phase II clinical trial of Topical Interferon Alpha-2b in patients with anogenital warts
("AGW") in Sweden and Germany is progressing on track.
Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts
with multiple HPV types and failure of therapeutic vaccination.
External anogenital warts
are frustrating for patients, who find them to be agonizing and repugnant in appearance.
Gardisil targets HPV 6 and 11, which are associated with anogenital warts
, and HPV 16 and 18, which cause most cervical cancers.
However, less than half of the clinicians believed three statements that are consistent with current scientific evidence:</p> <pre> That most genital HPV infections clear without medical intervention (35%); that genital HPV types usually associated with anogenital warts
differ from types usually associated with cervical dysplasia and cancer (47%); and that anogenital warts
do not increase the risk of cancer at the same anatomic sites where warts are located (38%)
are the most common sexually transmitted viral disease in the United States.
HPV-6 and HPV-11 (low-risk types) are found in 25% of CIN I lesions and 90% of anogenital warts
Out estimate of the total medical cost attributable to an HPV infection in youth focused on costs associated with cervical abnormalities in women and external anogenital warts
in both men and women.
THE most commonly reported infections were anogenital warts
, non specific urethritis and chlamydia.
3] Of note, up to 48% of HIV-positive individuals with oral warts have a previous or concurrent history of cutaneous and/or anogenital warts